Zymeworks (ZYME) Total Liabilities (2021 - 2026)
Zymeworks (ZYME) posted Total Liabilities of $314.6 million for Q1 2026, up 303.23% sequentially from $78.0 million in Q4 2025, and up 212.89% YoY from $100.6 million in Q1 2025.
Analysis
Zymeworks (ZYME) Total Liabilities (2021 - 2026) Analysis & Trends
Zymeworks has reported Total Liabilities for 6 years, with the latest figure at $314.6 million in Q1 2026.
- Quarterly Total Liabilities rose 212.89% year-over-year to $314.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $314.6 million (up 212.89% YoY) and the FY2025 annual result came in at $78.0 million, down 37.24% from the prior year.
- Total Liabilities rose to $314.6 million in Q1 2026 per ZYME's latest filing, from $78.0 million in the prior quarter.
- Over five years, Total Liabilities peaked at $314.6 million in Q1 2026 and troughed at $73.9 million in Q2 2025.
- A 5-year average of $127.9 million and a median of $120.2 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2025 and 2026: Total Liabilities tumbled 37.24% in 2025, then soared 212.89% in 2026.
- Over 5 years, Total Liabilities stood at $155.8 million in 2022, then decreased by 25.48% to $116.1 million in 2023, then rose by 7.11% to $124.3 million in 2024, then sank by 37.24% to $78.0 million in 2025, then jumped by 303.23% to $314.6 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $314.6 million, $78.0 million, and $77.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 4.20 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.72 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 4.00 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 10.03 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Zymeworks | 2.13 Bn | 1.86 Bn | - | 316.60 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 316.60 Mn |
| Mar 31, 2026 | 314.63 Mn |
| Dec 31, 2025 | 78.03 Mn |
| Sep 30, 2025 | 77.21 Mn |
| Jun 30, 2025 | 73.88 Mn |
| Mar 31, 2025 | 100.56 Mn |
| Dec 31, 2024 | 124.32 Mn |
| Sep 30, 2024 | 120.17 Mn |
| Jun 30, 2024 | 109.47 Mn |
| Mar 31, 2024 | 115.75 Mn |
| Dec 31, 2023 | 116.07 Mn |
| Sep 30, 2023 | 132.02 Mn |
| Jun 30, 2023 | 153.14 Mn |
| Mar 31, 2023 | 127.21 Mn |
| Dec 31, 2022 | 155.77 Mn |
| Sep 30, 2022 | 120.51 Mn |
| Jun 30, 2022 | -222.28 Mn |
| Mar 31, 2022 | -282.44 Mn |
| Dec 31, 2021 | 140.04 Mn |
| Sep 30, 2021 | -278.93 Mn |